M&A Deal Summary |
|
|---|---|
| Date | 2008-03-07 |
| Target | FIC Médical SARL |
| Sector | Life Science |
| Buyer(s) | Recordati |
| Deal Type | Add-on Acquisition |
| Deal Value | 12M EUR |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1926 |
| Sector | Medical Products |
| Employees | 4,450 |
| Revenue | 2.3B EUR (2024) |
Recordati is an international pharmaceutical group dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, other Central and Eastern European countries, Turkey, North Africa, the United States of America, Canada, Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati was founded in 1926 and is based in Milan, Italy.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 17 |
| Sector: Life Science M&A | 3 of 10 |
| Type: Add-on Acquisition M&A Deals | 4 of 15 |
| Country: France M&A | 4 of 5 |
| Year: 2008 M&A | 1 of 2 |
| Size (of disclosed) | 12 of 13 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-09-28 |
Orphan Europe SARL
Paris La Défense, France Orphan Europe is a European pharmaceutical group specialized in rare diseases with headquarters in Paris. Orphan Europe is a European pharmaceutical company dedicated to the development, registration, marketing and distribution of unique drugs for the treatment of rare and orphan diseases. |
Buy | €135M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-10-29 |
Yeni Ilaç ve Hammaddeleri A.S.
Istanbul, Turkey Yeni Ilaç ve Hammaddeleri A.S. is a Turkish pharmaceutical company with headquarters near Istanbul. Yeni Ilaç is a well known Turkish pharmaceutical company dedicated to the production, marketing and sales of both proprietary and licensed drugs. Its products are well known and the company has a leading market position in the area of urology. The company is also engaged in contract manufacturing for other pharmaceutical companies. |
Buy | €48M |
